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Introduction
Thrombotic microangiopathy (TMA) syndromes are characterised by endothelial dysfunction, microangiopathic haemolytic anaemia and microvascular ischaemia, with diverse aetiologies which include drugs 1, 2 . Clinicians evaluating TMA patients must decide whether a particular drug is likely to have caused the disease. This difficult decision requires high quality evidence, and recent work has highlighted the difficulty of attributing a causal relationship 1 . TMA is typically a rare but serious adverse event which can occur after many years of treatment. As such, an association is unlikely to be detected in randomised controlled trial data 3 . Therefore, for the large majority of drugs, causality with TMA is inferred from isolated case reports, without wider analyses of drug safety data or experimental evidence 1 . This problem is exemplified by recombinant type I interferon therapies. Recombinant interferon-α and interferon-β therapies act through the common type I interferon receptor IFNAR, and are widely used for the treatment of neoplastic, autoimmune and infectious diseases 4 . Case reports have linked TMA to both interferon-α and interferon-β therapies, the main subclasses of type I interferon 5, 6 . Particular concern has been recently raised regarding interferonβ use in multiple sclerosis patients, where fatal cases of TMA have been observed 6, 7 . However a causal role for interferon remains to be demonstrated, and alternative confounding aetiologies such as other drugs, complement mutations and E.coli exposure have been suggested 6, 8 .
Establishing causation in drug safety is a major challenge. Frameworks have been proposed to support evidence of a causal association between disease and environmental factors, the best known of which are the Bradford-Hill criteria 9, 10 . Such frameworks include a potential role for biological and experimental studies in establishing causation.
As such the demonstration of causality in drug safety benefits from a multifaceted approach to the adverse drug event, encompassing analyses of individual cases, drug safety data and experimental evidence 10 . Critically, such analyses require accurate description of the adverse drug event of interest. This is particularly relevant to the study of TMA since this is a pathophysiologically heterogeneous syndrome, with at least nine primary TMA syndromes described 2 . It is also important to establish whether an adverse event is caused by the drug's active ingredient or by other drug components 11 12 . For example, renal failure caused by intravenous immunoglobulin therapy is associated with the high sucrose content of the drug, rather then the immunoglobulin itself, with important implications for understanding the adverse event and managing risk 11 .
To address these questions we performed a detailed clinical analysis of type I interferon-associated TMA cases presenting to a national TMA centre to identify important features of the clinical phenotype of this complication. We provide experimental evidence which suggests that the interferon protein itself directly causes microvascular disease, using a transgenic model of type I interferon (interferon-α1) toxicity. We subsequently consider the potential implications of these findings for the safety of patients receiving recombinant type I interferon therapies.
Methods

Patient evaluation and drug safety data
Patients with multiple sclerosis who developed thrombotic microangiopathy with interferon-β therapy were referred to the national TMA centre in Newcastle for further evaluation 13 . The study was approved by Newcastle and North Tyneside 1 Research Ethics Committee (MREC/1/3/83). Individual patient interferon dose was determined from patient records and adjusted for weight (mcg/kg). Dose-response was also further assessed through analysis of national spontaneous reporting data. Requests for safety data were submitted in the context of a registered patient safety audit (NHS Lothian DCNQIT417). Cases of interferon-associated thrombotic microangiopathy reported throughout the UK were identified through a request for spontaneous data submitted to the UK Medicines and
Healthcare products Regulatory Authority (MHRA). All spontaneously reported cases of thrombotic microangiopathy associated with recombinant interferon-β from 1999 to January 2016 to the MHRA were identified, using search criteria "haemolytic uraemic syndrome", "thrombotic thrombocytopenic purpura", "thrombotic microangiopathy" and "malignant hypertension". These cases represent all TMA cases spontaneously reported using the UK "Yellow Card" spontaneous reporting scheme as well as UK cases reported in the published literature.
Immunohistochemical analysis
Paraffin-embedded renal biopsies from patients with IFN-β-associated thrombotic microangiopathy were cut into 5 µm sections, rehydrated and boiled in sodium citrate buffer (pH 6.0). Sections were stained with mouse-anti-MxA (kind gift, Otto Haller, University of Freiburg; 1:400) followed by staining with EnVision™ G|2 System/AP Rabbit/Mouse (Dako) and counterstained with Mayer's hematoxylin (Merck).
In vitro effects of type I interferon on endothelial cells
BEND.5 immortalised mouse brain endothelial cells were plated at 5 x 10 5 15 . The fold-change for genes in interferon-α and interferon-β treated HUVECs were compared.
Analysis of microvasculature in a mouse model of type I interferon toxicity
The generation of transgenic mice (termed GFAP-IFNα1) with astrocyte-targeted, brain-specific production of type I interferon has been described previously 16 . Animal experiments were approved by University of Sydney Animal Ethics Committee (protocol number 5374). All animal experimental procedures were carried out in compliance with local procedures and guidelines. The microvasculature of non-transgenic littermate wildtype mice (WT), transgenic mice with low levels of astrocyte-derived IFN-α1 production (IFN Low ) and high levels of IFN-α1 production (IFN High ) was anti-rabbit avidin-biotinylated horseradish peroxidase complex (ABC kit; Vector, Burlingame, CA) used according to the manufacturer's instructions. The total number of microvascular abnormalities was counted across three X20 magnification fields per anatomical region, with counting performed blind to mouse genotype. One-way ANOVA was performed across groups for each anatomical region (GraphPad Prism Version 6.0d). For rescue experiments IFN High mice were crossed to IFNAR -/mice, which lack a functional type 1 interferon receptor 17 .
For RNA analysis, whole brain was removed and immediately snap-frozen in liquid nitrogen. Total RNA was extracted from the tissue samples using TriReagent (Sigma-Aldrich) performed according to the manufacturer's instructions.
The RNA concentration of the samples was determined by UV spectroscopy at 260 nm. For all probe sets, a fragment of the L32 gene was included and served as an internal loading control. The ribonuclease protection assays (RPAs)
for interferon response genes were performed and analyzed as described previously 18, 19 , with autoradiographs quantified by densitometry using Image J software, n=3 each group.
Vascular casting of interferon transgenic mice
Vascular casting of WT (n=2) and IFN High mice (n=6) was performed as previously described 20 , in accordance with National Institutes of Health Guidelines for Care and Use of Laboratory Animals. Briefly, deeply anesthetized animals were perfused with artificial cerebrospinal fluid (ACSF) containing Heparin, followed by 4% paraformaldehyde in PBS, and an injection of the resin Mercox (Ladd Research, Williston, VT). After resin curing, soft tissue was subsequently macerated followed by decalcification with 5% formic acid. Casts were washed, then dried by lyophilization, mounted on stubs, and sputter-coated with gold for routine scanning electron microscopy.
Results
Interferon-β causes a direct drug-induced thrombotic microangiopathy
In view of the recent regulatory concerns regarding the potential association between type I interferon therapy and TMA in multiple sclerosis patients 6 , we first performed a detailed analysis of the clinical features of interferon-β associated thrombotic microangiopathy. The clinical phenotype of new and index 6 cases of interferon-β associated TMA in multiple sclerosis patients was reviewed by the UK national thrombotic microangiopathy centre 13 (n=8, Table   1 , Figure 1 ). Microangiopathic haemolytic anaemia, renal failure and severe hypertension were universally seen and at least one other organ was affected, with prominent brain and cardiac involvement. (Figure 1A-D 26 . This observation of low weight was replicated in an independent case series 7 . Therefore patients who developed TMA received a significantly higher weight-adjusted interferon dose than those who did not develop the complication ( Figure 1E P<0.001 t-test). To confirm this dose-dependence we requested national spontaneous reporting data from the UK Medicines and Healthcare Products Regulatory Agency. This showed that all cases were associated with a dose of interferon-β in excess of 50mcg per week, with 92% of cases associated with the highest available dose ( Figure 1F ). Evidence of interferon bioactivity ( Figure 1G -H) was detected in patient renal biopsies, and anti-interferon antibodies were not detected in any patient, consistent with a direct rather than immune-mediated effect of the drug. Taken together these results suggest that interferon-β causes a toxic drug-induced thrombotic microangiopathy in multiple sclerosis patients.
Thrombotic microangiopathy is observed with all type I interferon subtypes
We next asked whether TMA was observed with all subtypes of recombinant type I interferon therapies in clinical use.
The type I interferon family of proteins consists of a family of 13 alpha subtypes and a single major beta subtype 27 .
These subtypes exhibit structural similarity and exert their biological activity via the common type I interferon receptor IFNAR (Figure 2A ). Recombinant interferon-α therapies are used to treat a broad range of diseases such as CML, hepatitis C and melanoma. Systematic review of the literature shows that thrombotic microangiopathy has been reported as a complication of every subtype of recombinant type I interferon in clinical use; IFNα2a, IFNα2b, IFNβ1a
and IFNβ1b ( Figure 2B , Supplementary Figure 1 ).
We next compared the detailed clinical phenotype described here of interferon-β associated TMA with a comparably detailed analysis of a series of interferon-α associated TMA, analysed at a specialised centre 5 (n=8 both groups). A similar clinical phenotype is observed in both case series ( Supplementary Table 2 ). Specifically, interferon-α and interferon-β TMA were associated with long-term therapy at high-doses 5 . Both groups displayed severe hypertension, predominant involvement of the renal microvasculature, moderate thrombocytopenia and a poor renal outcome. All published cases are summarised in the supplementary tables 3 and 4 and confirm that this clinical picture is seen in the majority of patients. Furthermore, the transcriptomic response of human endothelial cells to both human interferon-α and interferon-β are highly correlated ( Figure 2C , r=0.97) 15 . Therefore thrombotic microangiopathy can occur with all subtypes of recombinant type I interferon therapies, and these subtypes exert an almost identical effect on endothelial cells.
Thrombotic microangiopathy is associated with "interferonopathic" disease
An activated type I interferon response can be induced by recombinant protein therapies, but can also occur spontaneously in patients in whom endogenous levels of type I interferon are pathologically elevated. These "interferonopathic" diseases include monogenic disorders of interferon dysregulation, as well as more common autoimmune diseases such as SLE 28, 29 . We reviewed pathological findings from patients with different diseases where transcriptomic evidence of an interferon signature has been reported, and identified an association with histopathological evidence of thrombotic microangiopathy, which is exceptionally rare as a spontaneous disease 30 ( Supplementary Figure 1 ). Therefore thrombotic microangiopathy is observed in states of elevated endogenous and exogenous type I interferon in humans.
Type I interferon signalling is species specific, limiting interpretation of preclinical toxicity tests
Given this clinical evidence that TMA is a manifestation of interferon toxicity, we next sought to provide experimental evidence that the recombinant protein itself can cause the small vessel disease observed in the patients described here. To address whether interferon can directly cause microangiopathic disease in rodent models, we first evaluated available preclinical toxicity data used in the clinical development of both recombinant interferon -α and -β therapies 31, 32 . No reports of microvascular toxicity were recorded in extensive preclinical testing of human recombinant protein in rodents. However, type I interferon signalling is highly species specific, and human interferon -α and -β do not cause upregulation of interferon response genes in mouse endothelial cells ( Figure 3A,B) . Therefore, preclinical rodent toxicity models cannot be used to evaluate whether interferon causes endothelial toxicity 31, 32 .
Transgenic overexpression of type I interferon causes a spectrum of microangiopathic disease, including changes seen in patient biopsies
To overcome the problem of species disparity of interferon action, we utilised a species-matched transgenic mouse model to evaluate the effects of chronic type I interferon exposure on small blood vessels. In our model, type I interferon (IFNα1) is transgenically produced in the brain at zero (WT), low (IFN Low ) or high (IFN High ) levels, leading to focal graded activation of the interferon response via IFNAR ( Figure 4A ) 16 . Quantitative histopathological analyses identified a dose-dependent spectrum of microvascular disease, including endothelial hypertrophy and intimal thickening, microaneuryms and perivascular inflammatory infiltrates ( Fig. 4C -F, Figure 5 , Figure 6 ). This microangiopathy was observed across anatomical regions and was dose-dependent ( Figure 4G , Figure 6D P<0.001 one-way ANOVA).
The three-dimensional morphology of small blood vessels are difficult to assess using conventional histopathological techniques, therefore we performed scanning electron microscope analysis of microvascular casts. This confirmed widespread microvascular abnormalities in the brain, with prominent variations in microvascular calibre including luminal stenosis and occlusions, ectasia and microaneurysms ( Fig. 5, Figure 6K Figure 7A,B) .
To confirm this microvascular pathology is caused by activation of the interferon response through the type I interferon receptor IFNAR, we crossed IFN High mice with mice that were null for the type I interferon receptor 17 , generating
IFN High x IFNAR1 -/mice. Both upregulation of interferon response genes (IRG) and microvascular disease were absent in IFN High x IFNAR1 -/mice, confirming a critical role of IFNAR in mediating disease (Figure 7C,D) .
Taken together these data suggest that type I interferon therapies cause a dose-dependent thrombotic microangiopathy and the interferon protein itself can cause microangiopathic disease.
Discussion
To date, unambiguous evidence of a causal association between type I interferon therapies and thrombotic microangiopathy has been lacking. This lack of evidence, together with a limited understanding of the serious adverse event, has hampered risk mitigation measures for these drugs and makes the clinical decision as to whether to stop interferon treatment in patients with TMA difficult. Thrombotic microangiopathy is a particularly challenging adverse drug event to study since it is rare and may occur after prolonged exposure to the drug. As such, randomised clinical trials are not powered to identify a causal association 3, 33 . The detection of rare or delayed adverse events which occur outside trials typically relies on analysis of case reports and signal detection through spontaneous reporting data 3 .
This approach is subject to bias and confounding and therefore even if an association is identified, a causal relationship cannot be inferred. A number of conceptual frameworks have been proposed when considering how to infer causality from observational clinical data 10, 34 . Some of these frameworks, such as the well-known Bradford-Hill criteria 10 , suggest that experimental evidence can provide an important role in establishing causation by demonstrating biological plausibility, and direct evidence of causation in model systems. Our analyses of clinical, drug safety and experimental data satisfy the Bradford-Hill criteria and therefore support a causal link between type I interferon therapy and thrombotic microangiopathy (Supplementary Table 5 ).
Careful definition of the adverse event of interest is central to the study of drug side-effects 9 . This is of particular relevance here since many cases of interferon-associated TMA have been reported using diverse terms including HUS 7 , TTP 35 or malignant hypertension 35, 36 , each implying a different pathophysiological process. It is therefore an important first step to define the clinical syndrome through a centre with expertise in the evaluation of this complex condition. Our analyses of cases suggest that interferon-β therapy is associated with a direct drug-induced thrombotic We propose that the most appropriate working descriptive term for this complication is "type I interferon-associated thrombotic microangiopathy".
We have tested the hypothesis that type I interferon itself can directly cause microvascular disease. This hypothesis cannot be evaluated in preclinical rodent models due to the species-specificity of type I interferon signalling. We have therefore studied two complementary "species-matched" states of elevated type I interferon in mice and humans.
Firstly, our mouse model here provides experimental advantage over preclinical rodent models, through speciesmatching of interferon, and allows evaluation of the chronic effects of interferon exposure. Analysis of the microvasculature of this model demonstrates that type I interferon causes a spectrum of microangiopathy, with features that overlap with microvascular disease observed in the patients we describe. Secondly we show that TMA, which is exceptionally rare as a spontaneous disease 30 , is consistently observed across a broad spectrum of human "interferonopathic" diseases. In these disease states, interferon levels are spontaneously elevated in the context of activated innate immunity 27 . As such they might be considered by the Bradford-Hill criteria to represent an "analogous" system of human interferon toxicity. These diseases include rare genetic disorders of interferon dysregulation 4, 27, 28 , as well as more common autoimmune disorders such as SLE 37 . The precise subtypes of type I interferon which are elevated in these disease states are not yet fully described, but activation of the interferon response downstream of IFNAR is typically observed 28 . Microangiopathy is a major cause of organ damage in these patients ( Supplementary   Figure 1) 38, 39 . For example, 25% of patients with SLE affecting the kidney have evidence of TMA on renal biopsy 40, 41 and microangiopathy is a dominant brain pathology in patients with SLE 31 . Therefore microangiopathic disease is consistently seen in mouse and human states of aberrantly elevated type I interferon. It is notable that in both patients and the mouse model we describe, microangiopathy is the dominant pathological feature, with microvascular thrombosis a less prominent feature. The lack of thrombosis on biopsy in many TMAs has resulted in a recent call for a change in nomenclature from TMA to microangiopathy with or without thrombosis to reflect this incongruity 42 .
These findings are relevant to clinicians who must decide whether to stop recombinant type I interferon therapy in patients who develop thrombotic microangiopathy. Our data suggests a causal association and therefore the drug should be stopped at the earliest opportunity given the serious ensuing morbidity. Furthermore our findings are of relevance to risk mitigation strategies since they raise the possibility of stratification and monitoring. In particular detailed retrospective analysis of clinical features and biopsies of cases suggests that type I interferon causes a chronic TMA, which evolves over weeks to months, with a detectable prodrome (supplementary table 6 ). At present, renal function monitoring and blood pressure monitoring is not mandated for patients receiving type I interferon therapies and none of the patients described here were actively monitored for this complication. Therefore, despite a potential window of opportunity for early recognition, all patients presented at a late stage to emergency or critical care facilities. This late presentation is characterised by fulminant disease and organ failure, sometimes with fatal consequences.
Additional blood pressure and renal function monitoring for TMA have subsequently been introduced across Scotland following concerns about the severity and incidence of this complication in multiple sclerosis patients, where an incidence of ~1:1000 patient-years has been observed in patients treated with high-dose interferon-β 6 (supplementary figure 2) . This monitoring has led to prompt cessation of interferon-β in patients who have developed severe/accelerated hypertension associated with mild renal dysfunction. Since the implementation of targeted monitoring, no patients have developed fulminant organ failure due to interferon-associated TMA (supplementary Figure 2B ). We suggest that further consideration should be given to risk mitigation measures for this serious adverse drug event.
In summary we have shown that type I interferon therapies cause a direct dose-dependent thrombotic microangiopathy and the interferon protein itself can directly damage small blood vessels. The chronic and dosedependent nature of this complication identifies an opportunity to reduce risk to the large numbers of patients exposed to these drugs. These findings should facilitate and stimulate definitive and rigorous pharmacoepidemiological study of this serious adverse event, with an emphasis on quantification of risk and the potential for mitigation across the available type I interferon therapies. In the meantime, clinicians should be aware of this association when assessing patients and stop recombinant type I interferon therapies at the earliest stage in patients who develop TMA. Supplementary Table 1 . Following diagnostic reevaluation the clinical phenotype of the cases was uniformly consistent with a direct drug-induced thrombotic microangiopathy 2, 24 .
